T6394

AS-604850 is a specific and ATP-competitive PI3Kγ inhibitor (IC50: 250 nM), 18-fold more selective for PI3Kγ than PI3Kα, and over 80-fold selectivity for PI3Kγ than PI3Kδ/β.

B026 is a selective, orally active inhibitor of p300/CBP histone acetyltransferase (p300/CBP HAT) that acts on p300 (IC50: 1.8 nM) and CBP (IC50: 9.5 nM). b026 exhibits anticancer effects on androgen receptor positive (AR+) prostate cancer cells.

α-Glycosidase-IN-1 (compound MZ7) is a potent inhibitor of α-GLY (α-glycosidase) with an IC50 of 44.72 nM and a Ki of 44.74 nM. It also inhibits human carbonic anhydrase isozymes I (hCA I) and II (hCA II) with IC50 values of 104.87 nM and 100.04 nM, respectively, and acetylcholine esterase (AChE) with an IC50 value of 654.87 nM. α-Glycosidase-IN-1 is applicable in the study of diabetes, Alzheimer's disease, ulcers, heart failure, epilepsy, and various other diseases.

WNY1613 is a potent and selective PI3Kδ inhibitor with a piperazinone-containing purine scaffold, exhibiting anti-NHL effects both in vitro and in vivo by inhibiting phosphorylation of downstream components of PI3K in NHL cell lines and inducing apoptosis in cancer cells.

COX-2-IN-10 is a potent COX-2 inhibitor that exhibits inhibitory effects on the production of IL-6, TNF-α, and IL-1β, and inhibits PGE2 production in a concentration-dependent manner with an IC50 value of 2.54 μM. Additionally, COX-2-IN-10 inhibits the expression of iNOS and COX-2 at both mRNA and protein levels.

4BAB (compound 29) is an irreversible inhibitor of glyoxalase I (GLO1) with notable anticancer activity.

Antitubercular agent-19 is an antitubercular agent. antitubercular agent-19 showed good antitubercular effects against MTB H37Rv and MDR-MTB (MIC <0.016 μg/ml). antitubercular agent-19 showed low cytotoxicity and relatively high acute lethality in BALB/c mice. Antitubercular agent-19 exhibited low cytotoxicity and relatively high acute lethal toxicity in BALB/c mice.

Cap-dependent endonuclease-IN-14 is a potent inhibitor of cap-dependent nucleic acid endonucleases (CEN) and can inhibit the replication of influenza viruses, showing potential for treating viral infections caused by influenza viruses.

GRPR antagonist-1 is a potent antagonist of the gastrin-releasing peptide receptor (GRPR) and displays cytotoxicity to certain cancer cells, including PC3 cells (IC50: 4.97 μM), Pan02 cells (IC50: 4.36 μM), and HGC-27 cells (IC50: 3.40 μM). It reduces Bcl-2 levels, increases Bax levels, inhibits HGC-27 cell viability, and induces apoptosis, thereby exhibiting anti-cancer effects.

PD-1/PD-L1-IN-16, a potent inhibitor of PD-1/PD-L1 (IC50: 53.2 nM), has demonstrated research potential for tumor immunotherapy.

HIV-1 protease-IN-2 is a potent inhibitor of HIV-1 protease (IC50: 2.53 nM) and exhibits antiviral effects against DRV (Darunavir) sensitive and drug-resistant HIV-1 mutants.